Introduction/Background Vulvar cancer is rare. Its incidence is around one case per 100,000 women. It is a squamous cell carcinoma in more than 90% of cases. Our study aims to analyze the clinical and outcome aspects of vulvar cancers.

Methodology This was a descriptive and retrospective study over five years. We included all patients admitted with vulvar cancers. We collected and analyzed medical data and management. We pay particular attention to the prognostic factors such as recurrence and survival.

Results During our study period, fifteen women met our criteria. The mean age was 64 years [44–84]. Only one patient still has her menstruation and hasn’t had any pregnancy. The average time for the consultation was 4 months. The clinical tumor size was more than 1 cm in all cases. All patients underwent partial or total vulvectomy with lymph node resection in ten cases. Histologically, thirteen of these cases were squamous cell carcinoma, one was verrucous carcinoma and, one was melanoma. Additional treatment consisted of chemotherapy and, or radiotherapy. Five patients progressed to recurrence in an average of six months.

Conclusion Cancers of the vulva are rare and occur at a late age. Squamous cell carcinoma being the main tumor. Despite the quality of management, the risk of recurrence is not negligible. Close and multidisciplinary surveillance is essential.

Disclosures No conflict of interest.